Governor overhauls Maryland medical cannabis commission

Maryland Gov. Larry Hogan overhauled the state’s 16-member medical cannabis commission this week, making 10 appointments and doubling its minority representation.

Hogan filled three vacancies on the panel, replaced six commissioners whose terms had expired and reappointed a 10th commissioner, assistant comptroller John Gontrum, according to the Baltimore Business Journal.

Critics of the Maryland Medical Cannabis Commission – including the Legislative Black Caucus – have charged the panel lacked diversity and failed in a mandate to ensure minorities are represented among grow and dispensary licensees.

The other nine appointees, according to the Business Journal:

  • Charles LoDico, a senior chemist/toxicologist for the Department of Health
  • Barry Pope, a drug rebate manager and PBM clinical pharmacist for Conduent State Healthcare
  • Brian Lopez, a partner and executive vice president for Osprey Property Co.
  • Alvin Davis, a partner at Cumberland Anesthesia and Pain Management Associates who specializes in cardiac and thoracic anesthesia
  • Jeffrey Gahler, the Harford County sheriff since 2014
  • Charles Smith III, state’s attorney for Frederick County since 2007
  • Rahel Rhodes, a horticulture associate agent and master gardener coordinator for the University of Maryland Extension – Queen Anne’s County
  • Ehsan Abdeshahian, a staff physician with specialties in pain and sports medicine for Advanced Pain Management Specialists
  • Scott Welsh, the owner of Maryland Flower and Foliage, where he maintains 160,000 square feet of greenhouse space and 100,000 square feet of outdoor growing areas
Daily News | Briefs | Maryland Medical Cannabis Business & Marijuana Legal News


  1. anne absalom July 7, 2017
  2. Liesl July 18, 2017

Leave a Reply

Your email address will not be published. Required fields are marked *

Please note: Comments are moderated by our editors who do their best to approve comments ASAP. As Marijuana Business Daily is focused on business, we approve comments that are specifically relevant to industry professionals. General opinions and questions about cannabis may not be posted.